The angiotensin AT1 receptor antagonist irbesartan has near-peptide affinity and potently blocks receptor signaling

European Journal of Pharmacology

Volumn 384, Issue 1, 1999, Pages 81-89

  Hines, John ^a   Fluharty, Steven J ^a   Sakai, Randall R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Angiotensin AT1 receptor; Angiotensin II; Inositol trisphosphate; Irbesartan; Peripheral tissue

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II [1 SARCOSINE 8 ISOLEUCINE]; INOSITOL TRISPHOSPHATE; IODINE 125; IRBESARTAN; LOSARTAN POTASSIUM; NICOTINOYLTYROSYL(N BENZYLOXYCARBONYLARGINYL)LYSYLHISTIDYLPROLYLISOLEUCINE; RADIOLIGAND; TASOSARTAN;

ADRENAL GLAND; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ELECTROLYTE BALANCE; HYPERTENSION; HYPOPHYSIS; INGESTION; KIDNEY; LIVER; LIVER CELL MEMBRANE; MALE; NONHUMAN; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

ADRENAL GLANDS; ANGIOTENSIN II; ANIMALS; BINDING, COMPETITIVE; BIPHENYL COMPOUNDS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; IODINE RADIOISOTOPES; KIDNEY; LIVER; LOSARTAN; MALE; PC12 CELLS; PITUITARY GLAND; PYRIMIDINES; RADIOLIGAND ASSAY; RATS; RATS, INBRED F344; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; SIGNAL TRANSDUCTION; TETRAZOLES;

EID: 0032761340     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00662-7     Document Type: Article

References (46)

1. Aguilera G., Harwood J.P., Wilson J.X., Morell J., Brown J.H., Catt K.J. Mechanisms of action of corticotropin-releasing factor and other regulators of corticotropin release in rat pituitary cells. J. Biol. Chem. 258:1983;8039-8045.
2. 8-angiotensin II (saralasin) in hypertensive subjects. Circ. Res. 40:1977;243-250.
3. Balla T., Baukal A.J., Eng S., Catt K.J. Angiotensin II receptor subtypes and biological responses in the adrenal cortex and medulla. Mol. Pharmacol. 40:1991;401-406.
4. Bernstein K.E., Berk B.C. The biology of angiotensin receptors. Am. J. Kidney Dis. 22:1993;745-754.
5. Berridge M.J., Downes C.P., Hanley M.R. Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. Biochem. J. 206:1982;587-592.
6. 2 subtype. J. Med. Chem. 34:1991;3248-3260.
7. Brunner H.R. The new angiotensin II receptor antagonist, irbesartan-pharmacokinetic and pharmacodynamic considerations. Am. J. Hypertens. 10:1997;311S-317S.
8. 1-like receptor with reduced affinity for DuP 753. FEBS Lett. 343:1994;146-150.
9. 1 subtype angiotensin II receptor antagonist. J. Pharmacol. Exp. Ther. 265:1993;826-834.
10. Chaki S., Inagami T. New signaling mechanism of angiotensin II in neuroblastoma Neuro-2A cells: activation of soluble guanylyl cyclase via nitric oxide synthesis. Mol. Pharmacol. 43:1993;603-608.
11. Chiu A.T., Herblin W.F., McCall D.E., Ardecky R.J., Carini D.J., Duncia J.V., Pease L.J., Wong P.C., Wexler R.R., Johnson A.L., Timmermans P.B.M.W.M. Identification of angiotensin II receptor subtypes. Biochem. Biophys. Res. Commun. 165:1989;196-203.
12. Chiu A.T., McCall D.E., Price W.A., Wong P.C., Carini D.J., Duncia J.V., Wexler R.R., Yoo S.E., Johnson A.L., Timmermans P.B.M.W.M. In vitro pharmacology of DuP 753. Am. J. Hypertens. 4:1991;282S-287S.
13. Christophe B., Libon R., Cazaubon C., Nisato D., Manning A., Chatelain P. Effects of irbesartan (SR 47436/BMS 186295) on angiotensin II-induced pressor responses in the pithed rat: potential mechanisms of action. Eur. J. Pharmacol. 281:1995;161-171.
14. Cody R.J. Conceptual and therapeutic approaches to inhibition of the renin-angiotensin system in chronic heart failure. J. Cardiovasc. Pharmacol. 8:1986;S58-S65.
15. Fitzsimons J.T. Angiotensin, thirst, and sodium appetite. Physiol. Rev. 78:1998;583-686.
16. 1 angiotensin II receptor expressed in guinea pig heart. J. Endocrinol. 154:1997;133-138.
17. Gavras H., Gavras I. Angiotensin converting enzyme inhibitors. Properties and side effects. Hypertension. 11:1988;II37-II41.
18. Griendling K.K., Ushio-Fukai M., Lassegue B., Alexander R.W. Angiotensin II signaling in vascular smooth muscle. New concepts. Hypertension. 29:1997;366-373.
19. Kiron M.A.R., Soffer R.L. Purification and properties of a soluble angiotensin II-binding protein from rabbit liver. J. Biol. Chem. 264:1989;4138-4142.
20. Kobayashi M., Furukawa Y., Chiba S. Positive chronotropic and inotropic effects of angiotensin II in the dog heart. Eur. J. Pharmacol. 50:1978;17-25.
21. Lees K.R., Squire I.B., Reid J.L. The clinical pharmacology of ACE inhibitors: evidence for clinically relevant differences? Clin. Exp. Pharmacol. Physiol., Suppl. 1992;49-53.
22. Lu D., Yang H., Raizada M.K. Angiotensin II regulation of neuromodulation: downstream signaling mechanism from activation of mitogen-activated protein kinase. J. Cell Biol. 135:1996;1609-1617.
23. Lu D., Yu K., Paddy M.R., Rowland N.E., Raizada M.K. Regulation of norepinephrine transport system by angiotensin II in neuronal cultures of normotensive and spontaneously hypertensive rat brains. Endocrinology. 137:1996;763-772.
24. Man in't Veld A.J. Clinical overview of irbesartan: expanding the therapeutic window in hypertension. J. Hypertens. 15:1997;S27-S33.
25. Marino M.R., Langenbacher K.M., Raymond R.H., Ford N.F., Lasseter K.C. Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis. J. Clin. Pharmacol. 38:1998;347-356.
26. Molloy C.J., Taylor D.S., Weber H. Angiotensin II stimulation of rapid protein tyrosine phosphorylation and protein kinase activation in rat aortic smooth muscle cells. J. Biol. Chem. 268:1993;7338-7345.
27. Naftilan A.J., Pratt R.E., Dzau V.J. Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J. Clin. Invest. 83:1989;1419-1424.
28. Nakashima A., Angus J.A., Johnston C.I. Chronotropic effects of angiotensin I, angiotensin II, bradykinin and vasopressin in guinea pig atria. Eur. J. Pharmacol. 81:1982;479-485.
29. Pals D.T., Masucci F.D., Denning G.S. Jr., Sipos F., Fessler D.C. Role of the pressor action of angiotensin II in experimental hypertension. Circ. Res. 29:1971;673-681.
30. Peach M.J., Dostal D.E. The angiotensin II receptor and the actions of angiotensin II. J. Cardiovasc. Pharmacol. 16:1990;S25-S30.
31. 1 nonpeptide angiotensin II receptor antagonist, by rat, monkey and human hepatic microsomal fractions. J. Pharmacol. Exp. Ther. 271:1994;91-99.
32. Powell J.R., Reeves R.A., Marino M.R., Cazaubon C., Nisato D. A review of the new angiotensin II-receptor antagonist irbesartan. Cardiovasc. Drug Rev. 16:1998;169-194.
33. Reeves R.A., Lin C.-S., Kassler-Taub K., Pouleur H. Dose-related efficacy of irbesartan for hypertension - an integrated analysis. Hypertension. 31:1998;1311-1316.
34. 1 receptor antagonist, on blood pressure in conscious cynomolgus monkeys. Br. J. Pharmacol. 111:1994;145-150.
35. Skidgel R.A., Erdos E.G. The broad substrate specificity of human angiotensin I converting enzyme. Clin. Exp. Hypertens. A9:1987;243-259.
36. Steckelings U.M., Bottari S.P., Unger T. Angiotensin receptor subtypes in the brain. Trends Pharmacol. Sci. 13:1992;365-368.
37. Timmermans P.B.M.W.M., Wong P.C., Chiu A.T., Herblin W.F., Benfield P., Carini D.J., Lee R.J., Wexler R.R., Saye J.A.M., Smith R.D. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol. Rev. 45:1993;205-251.
38. Timmermans P.B.M.W.M., Duncia J.V., Carini D.J., Chiu A.T., Wong P.C., Wexler R.R., Smith R.D. Discovery of losartan, the first angiotensin II receptor antagonist. J. Hum. Hypertens. 9:1995;S3-S18.
39. 2 receptors in the rat brain. Mol. Pharmacol. 41:1992;290-297.
40. Unger T., Gohlke P. Converting enzyme inhibitors in cardiovascular therapy: current status and future potential. Cardiovasc. Res. 28:1994;146-158.
41. Vallotton M.B. The renin-angiotensin system. Trends Pharmacol. Sci. 8:1987;69-74.
42. 2 receptors. Biochem. Biophys. Res. Commun. 181:1991;1365-1371.
43. Williams G.H. Converting-enzyme inhibitors in the treatment of hypertension. N. Engl. J. Med. 319:1988;1517-1525.
44. Wong P.C., Timmermans P.B.M.W.M. Historical development of losartan (DuP 753) and angiotensin II receptor subtypes. Blood Pressure. 5:1996;11-14.
45. 2 receptor heterogeneity. Mol. Brain Res. 45:1997;108-116.
46. Yu K., Lu D., Rowland N.E., Raizada M.K. Angiotensin II regulation of tyrosine hydroxylase gene expression in the neuronal cultures of normotensive and spontaneously hypertensive rats. Endocrinology. 137:1996;3566-3576.